Novavax Gets a Big Win for Its Flu Vaccine in Phase 3 Trial
On Tuesday, vaccine-specialist Novavax (NASDAQ: NVAX) reported positive news from the phase 3 trial for its flu vaccine, NanoFlu: The treatment met both the primary and secondary endpoints of the study. The stock was up 36% in early trading.
"These strong Phase 3 results align with and validate our previous clinical trials, in which NanoFlu showed higher HAI antibody responses than the leading flu vaccine for older adults," said CEO Stanley Erck. "We expect that both Fast Track designation and the accelerated approval pathway from the FDA will help Novavax bring NanoFlu to market as quickly as possible to address the serious public health threat of influenza."
Image Source: Getty Images
Source Fool.com
